EHD3

Across TCGA pan-cancer cohorts, EHD3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EHD3 data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher EHD3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated EHD3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and UCEC are the cancer types where EHD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.798	0.373	<.001	34	view →
LUAD	OS	Tertile	All	0.879	0.577	.001	17	view →
UCEC	DFS	Tertile	III,IV	0.485	1.000	.049	8	view →
HNSC	DFS	Median	III,IV	0.882	0.681	.002	6	view →
PDAC	OS	Median	III,IV	0.788	0.389	.026	4	view →
LSCC	DFS	Median	II,III,IV	0.695	0.872	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EHD3–CCRCC (DFS)

Open the CCRCC breakdown →